10. Diffuse Alveolar Hemorrhage

Quick Recap

Nests under Acute Respiratory Failure / ARDS mimics. Often presents as part of pulmonary-renal syndrome — universally fatal if unrecognized and untreated.

1. Definition

Diffuse alveolar hemorrhage (DAH) = bleeding into the alveolar spaces from the pulmonary microvasculature (capillaries, not bronchial arteries as in focal massive hemoptysis), producing diffuse bilateral infiltrates, anemia, and (variably) hemoptysis. Hemoptysis is ABSENT in up to 30% of DAH cases — its absence does not exclude the diagnosis.

Pulmonary-renal syndrome (PRS) = DAH + rapidly progressive glomerulonephritis (RPGN); a specific high-acuity subset requiring urgent recognition.

2. Pathophysiology

Three histopathologic patterns: pulmonary capillaritis (neutrophilic infiltration and destruction of alveolar capillary walls — classic for ANCA-associated vasculitis and anti-GBM disease), bland pulmonary hemorrhage (no inflammation — coagulopathy, anticoagulation, mitral stenosis), and diffuse alveolar damage (DAH as a component of ARDS/AIP). Capillaritis-associated DAH reflects immune complex or ANCA-mediated small-vessel injury; when the same process affects glomerular capillaries, pulmonary-renal syndrome results.

Causes:

ANCA-associated vasculitis subtype comparison:

3. Immediate Stabilization (ABCDE)

Airway/Breathing: maintain adequate oxygenation; provide ventilatory support with adequate PEEP if needed (recruits flooded alveoli, similar rationale to ARDS management) — treat as an ARDS-pattern hypoxemic respiratory failure while diagnostic workup proceeds in parallel, not sequentially.

Circulation: transfuse for significant anemia/ongoing blood loss; correct any coagulopathy contributing to bleeding (reverse anticoagulation, correct severe thrombocytopenia) regardless of whether coagulopathy is the primary cause or an amplifying factor.

Disability/Exposure: screen for extrapulmonary vasculitis manifestations that support diagnosis and localize disease activity — purpuric rash, arthralgias/arthritis, mononeuritis multiplex, sinusitis, scleritis/episcleritis, cerebral ischemia signs.

Checklist:

4. Focused History

Hemoptysis (present or not), dyspnea onset tempo, constitutional symptoms (fever, weight loss — vasculitis), joint pains/arthritis, rash, sinus symptoms/epistaxis/hearing loss (GPA), asthma history with eosinophilia (EGPA), known SLE/systemic sclerosis/inflammatory myopathy/rheumatoid arthritis, anticoagulant use, recent hematopoietic transplant, mitral valve disease, recent infection, drug exposures, hematuria/dark urine (renal involvement).

5. Examination + POCUS

Diffuse bilateral crackles, tachypnea; purpuric rash, oral/nasal ulcers, saddle-nose deformity, scleritis/episcleritis, signs of mononeuritis multiplex (asymmetric sensorimotor deficits), joint swelling, signs of pericarditis/myocarditis.

POCUS: diffuse bilateral B-lines (similar pattern to ARDS/cardiogenic edema — not distinguishing on its own); cardiac views to exclude concurrent myocarditis/pericardial involvement and to help exclude a purely cardiogenic explanation.

6. Syndrome Identification

Diffuse alveolar filling syndrome mimicking ARDS radiographically, but with a distinct differential and a fundamentally different first-line therapy (immunosuppression rather than purely supportive lung-protective ventilation) — recognizing DAH as the underlying process, not just "ARDS," changes management.

7. Differential Diagnosis

See Section 2 causes table. Key distinguishing move: exclude ARDS from a non-immune cause and cardiogenic pulmonary edema first via clinical context/echo, then pursue the DAH-specific workup (Section 9) if the pattern (anemia, possible hemoptysis, renal involvement, autoimmune features) fits.

8. Severity Assessment

No dedicated DAH-specific severity score; use general ICU severity tools (SOFA/APACHE II) plus the presence/absence of renal involvement (pulmonary-renal syndrome carries the worst prognosis if untreated) and degree of hypoxemia (Berlin-style P/F ratio tracking, as management parallels ARDS supportive care).

9. Investigations

Labs: CBC with Hb/platelets (trend for ongoing bleeding), basic coagulation panel, hemolysis labs + peripheral smear (exclude TMA as cause), BUN/creatinine, urinalysis with spun sediment (RBC casts = most specific but often absent — their absence does NOT exclude renal involvement), serologies: ANA, ANCA (specify PR3/c-ANCA vs MPO/p-ANCA), anti-GBM antibody (95% sensitive, 99% specific for Goodpasture's), consider RF/anti-CCP and myositis panel if clinical picture suggests.

Imaging: CXR and/or CT chest — diffuse bilateral infiltrates/ground-glass opacities, indistinguishable from ARDS/edema on imaging alone.

Procedures:

• Flexible bronchoscopy with bronchoalveolar lavage (BAL) is the key confirmatory test — progressively bloodier return on sequential aliquots through a wedged bronchoscope confirms DAH (vs a single bloody return, which may just reflect procedural trauma). BAL should also be sent for infectious workup to exclude infection as the cause/co-driver before committing to immunosuppression.
• Lung biopsy usually NOT necessary for diagnosis
• Percutaneous renal biopsy is higher-yield than transbronchial lung biopsy for establishing a definitive histopathologic diagnosis when pulmonary-renal syndrome is present — involve nephrology early for this

10. Evidence-Based Management

Supportive (parallel to ARDS approach): maintain oxygenation, ventilatory support with adequate PEEP as needed, correct coagulopathy, transfuse for significant anemia.

Immunosuppression (do not delay if life-threatening and infection reasonably excluded):

• Pulse-dose corticosteroids: methylprednisolone 500-1,000 mg IV daily x3-5 days (some sources cite up to 7-15 mg/kg/day), followed by oral/parenteral maintenance equivalent to prednisone 1 mg/kg/day
• Cytotoxic/immunosuppressive agents depending on the specific diagnosis:
• ANCA-associated vasculitis: cyclophosphamide (oral 2-3 mg/kg/day or IV 15 mg/kg or 750 mg/m2) OR rituximab — RAVE trial showed similar outcomes between cyclophosphamide and rituximab in non-intubated patients with creatinine <4; MAINRITSAN trial showed rituximab superior to azathioprine for maintenance of remission
• Anti-GBM disease (Goodpasture's): corticosteroids + cyclophosphamide + plasma exchange (more clearly beneficial in anti-GBM disease specifically than in ANCA vasculitis)
• Plasma exchange: PEXIVAS trial showed plasma exchange did NOT reduce death/ESRD as a routine addition in ANCA-associated vasculitis overall; lower-quality data suggest possible benefit in patients at high risk of ESRD, on renal replacement therapy, or with active DAH specifically — individualize, do not apply routinely
• IVIG: additional option depending on specific diagnosis and clinical context
• Stress-dose steroids (hydrocortisone 50 mg IV q6h or equivalent) for any patient chronically on corticosteroids, given critical illness/procedural stress

ECMO: should be assessed for patients with refractory hypoxemia despite optimized supportive care — active bleeding and the need for anticoagulation on ECMO should NOT be considered an absolute contraindication; anticoagulation strategy can be modified/minimized on a case-by-case basis with the ECMO team.

11. Organ Support

Mechanical ventilation with adequate PEEP (ARDS-pattern supportive care), transfusion support, renal replacement therapy if concurrent RPGN causes renal failure, ECMO for refractory hypoxemia (bleeding is not an absolute contraindication).

12. Disease-Specific Therapy

See Section 10 — immunosuppressive regimen is tailored to the specific underlying diagnosis (ANCA vasculitis subtype, anti-GBM disease, SLE, etc.) in conjunction with rheumatology/nephrology.

13. Consultation Matrix

14. Monitoring Framework

Serial Hb trend (ongoing alveolar bleeding drops Hb without external blood loss), serial renal function/urine output, oxygenation trend (P/F ratio), response to immunosuppression assessed over days (BAL return character, radiographic improvement, Hb stabilization).

15. ICU Bundle Checklist (Daily)

16. Complications

Respiratory failure requiring prolonged ventilation, renal failure/ESRD if pulmonary-renal syndrome untreated, opportunistic infection from immunosuppression, cyclophosphamide toxicity (hemorrhagic cystitis, myelosuppression, infertility), recurrent DAH flares. Prevention: prompt immunosuppression once infection reasonably excluded, careful infection surveillance during immunosuppressive treatment. Rescue: ECMO for refractory hypoxemia, RRT for renal failure, escalation of immunosuppression (e.g., add rituximab/plasma exchange) for refractory disease.

17. Escalation & De-escalation

Escalate: worsening hypoxemia despite ventilatory support, falling Hb despite transfusion, worsening renal function -> intensify immunosuppression, consider plasma exchange (esp. anti-GBM or DAH-predominant high-risk ANCA vasculitis), ECMO evaluation.

De-escalate: stabilizing/improving oxygenation, Hb stable, BAL return clearing on repeat bronchoscopy if performed, renal function stable/improving -> steroid taper per underlying disease protocol, transition to maintenance immunosuppression.

18. ICU Discharge Criteria

Hemodynamically and respiratory stable, Hb stable without ongoing transfusion requirement, renal function stable or on an established RRT plan, immunosuppression regimen transitioned to maintenance phase with rheumatology/nephrology follow-up arranged, infection surveillance plan in place.

19. Documentation & Medicolegal Checklist

20. Key Guidelines

2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides (classification framework); KDIGO glomerulonephritis guidelines (renal component); institutional/society ANCA-associated vasculitis treatment guidance incorporating RAVE, MAINRITSAN, and PEXIVAS trial evidence.

21. Landmark Trials

• RAVE trial: rituximab non-inferior to cyclophosphamide for ANCA-associated vasculitis induction in non-intubated patients with creatinine <4.
• MAINRITSAN trial (+ long-term follow-up): rituximab superior to azathioprine for maintenance of remission and long-term survival in ANCA-associated vasculitis.
• PEXIVAS trial: plasma exchange did not reduce death/ESRD as a routine addition to standard therapy in severe ANCA-associated vasculitis; possible benefit remains in specific high-risk subgroups (active DAH, RRT-dependent, high ESRD risk) based on lower-quality evidence.
• GiACTA study (giant cell arteritis, referenced for comparison of biologic adjunct approach): tocilizumab as adjunct to steroids — illustrates the broader trend toward targeted biologic therapy in vasculitis, informing but not directly guiding DAH-specific practice.

22. Controversies

Routine use of plasma exchange in ANCA-associated vasculitis-related DAH remains unresolved post-PEXIVAS — the trial argues against routine use, but active DAH was one of the subgroups where lower-quality data still suggested possible benefit, leaving real practice variation. Choice between cyclophosphamide and rituximab for induction in severe/intubated patients (excluded from RAVE's primary comparison population) relies on extrapolated, lower-quality evidence. Anticoagulation strategy on ECMO in the setting of active alveolar bleeding requires individualized, evolving practice rather than a fixed protocol.

23. References

1. Pulmonary Renal Syndrome and Diffuse Alveolar Hemorrhage; ANCA-Associated Vasculitis chapters. Washington Manual of Critical Care, 4th ed, 2025 (Ch. 69).
2. Glomerular and Microvascular Disorders in the ICU. Washington Manual of Critical Care, 4th ed, 2025 (Ch. 62, renal section).
3. Jennette JC, Falk RJ, Bacon PA, et al. 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1):1-11.
4. Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis (RAVE). N Engl J Med. 2010;363(3):221-232.
5. Guillevin L, Pagnoux C, Karras A, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis (MAINRITSAN). N Engl J Med. 2014;371(19):1771-1780.
6. Walsh M, Merkel PA, Peh CA, et al. Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis (PEXIVAS). N Engl J Med. 2020;382(7):622-631.